Wechselwirkungen von Levothyroxin und Liothyronin

Larger doses may produce serious or even life-threatening manifestations of toxicity, particularly when given in association with sympathomimetic amines such as those used for their anorectic effects. (Fachinformation zu Levothyroxin und Liothyronin, Boxed Warning (umrahmter Warnhinweis))

Larger doses may produce serious or even life-threatening manifestations of toxicity, particularly when given in association with sympathomimetic amines such as those used for their anorectic effects. (Fachinformation zu Levothyroxin und Liothyronin, Boxed Warning (umrahmter Warnhinweis))

Larger doses may produce serious or even life-threatening manifestations of toxicity, particularly when given in association with sympathomimetic amines such as those used for their anorectic effects. (Fachinformation zu Levothyroxin und Liothyronin, Boxed Warning (umrahmter Warnhinweis))

Larger doses may produce serious or even life-threatening manifestations of toxicity, particularly when given in association with sympathomimetic amines such as those used for their anorectic effects. (Fachinformation zu Levothyroxin und Liothyronin, Boxed Warning (umrahmter Warnhinweis))

Larger doses may produce serious or even life-threatening manifestations of toxicity, particularly when given in association with sympathomimetic amines such as those used for their anorectic effects. (Fachinformation zu Levothyroxin und Liothyronin, Boxed Warning (umrahmter Warnhinweis))

Larger doses may produce serious or even life-threatening manifestations of toxicity, particularly when given in association with sympathomimetic amines such as those used for their anorectic effects. (Fachinformation zu Levothyroxin und Liothyronin, Boxed Warning (umrahmter Warnhinweis))

Larger doses may produce serious or even life-threatening manifestations of toxicity, particularly when given in association with sympathomimetic amines such as those used for their anorectic effects. (Fachinformation zu Levothyroxin und Liothyronin, Boxed Warning (umrahmter Warnhinweis))

Larger doses may produce serious or even life-threatening manifestations of toxicity, particularly when given in association with sympathomimetic amines such as those used for their anorectic effects. (Fachinformation zu Levothyroxin und Liothyronin, Boxed Warning (umrahmter Warnhinweis))

Patients suspected of developing thyrotoxicosis should be managed carefully to avoid abrupt withdrawal of beta-adrenergic blocking agents that might precipitate a thyroid storm. (Fachinformation zu Brimonidin und Timolol, Warnhinweise und Vorsichtsmaßnahmen)

Larger doses may produce serious or even life-threatening manifestations of toxicity, particularly when given in association with sympathomimetic amines such as those used for their anorectic effects. (Fachinformation zu Levothyroxin und Liothyronin, Boxed Warning (umrahmter Warnhinweis))

Larger doses may produce serious or even life-threatening manifestations of toxicity, particularly when given in association with sympathomimetic amines such as those used for their anorectic effects. (Fachinformation zu Levothyroxin und Liothyronin, Boxed Warning (umrahmter Warnhinweis))

Larger doses may produce serious or even life-threatening manifestations of toxicity, particularly when given in association with sympathomimetic amines such as those used for their anorectic effects. (Fachinformation zu Levothyroxin und Liothyronin, Boxed Warning (umrahmter Warnhinweis))

Larger doses may produce serious or even life-threatening manifestations of toxicity, particularly when given in association with sympathomimetic amines such as those used for their anorectic effects. (Fachinformation zu Levothyroxin und Liothyronin, Boxed Warning (umrahmter Warnhinweis))

Larger doses may produce serious or even life-threatening manifestations of toxicity, particularly when given in association with sympathomimetic amines such as those used for their anorectic effects. (Fachinformation zu Levothyroxin und Liothyronin, Boxed Warning (umrahmter Warnhinweis))

Larger doses may produce serious or even life-threatening manifestations of toxicity, particularly when given in association with sympathomimetic amines such as those used for their anorectic effects. (Fachinformation zu Levothyroxin und Liothyronin, Boxed Warning (umrahmter Warnhinweis))

Larger doses may produce serious or even life-threatening manifestations of toxicity, particularly when given in association with sympathomimetic amines such as those used for their anorectic effects. (Fachinformation zu Levothyroxin und Liothyronin, Boxed Warning (umrahmter Warnhinweis))

Presence of uncontrolled non-gonadal endocrinopathies (e.g., thyroid, adrenal, or pituitary disorders). (Fachinformation zu Choriogonadotropin alfa, Gegenanzeigen)

Clomiphene citrate tablets are contraindicated in patients with uncontrolled thyroid or adrenal dysfunction or in the presence of an organic intracranial lesion such as pituitary tumor (see INDICATIONS AND USAGE). (Fachinformation zu Clomifen, Gegenanzeigen)

When concomitant administration of corticosteroids and levothyroxine is required, administration of corticosteroid should precede the initiation of levothyroxine therapy to avoid adrenal crisis. (Fachinformation zu Dexamethason, Warnhinweise und Vorsichtsmaßnahmen)

Larger doses may produce serious or even life-threatening manifestations of toxicity, particularly when given in association with sympathomimetic amines such as those used for their anorectic effects. (Fachinformation zu Levothyroxin und Liothyronin, Boxed Warning (umrahmter Warnhinweis))

Larger doses may produce serious or even life-threatening manifestations of toxicity, particularly when given in association with sympathomimetic amines such as those used for their anorectic effects. (Fachinformation zu Levothyroxin und Liothyronin, Boxed Warning (umrahmter Warnhinweis))

Larger doses may produce serious or even life-threatening manifestations of toxicity, particularly when given in association with sympathomimetic amines such as those used for their anorectic effects. (Fachinformation zu Levothyroxin und Liothyronin, Boxed Warning (umrahmter Warnhinweis))

Patients suspected of developing thyrotoxicosis should be managed carefully to avoid abrupt withdrawal of beta-adrenergic blocking agents that might precipitate a thyroid storm. (Fachinformation zu Dorzolamid und Timolol, Warnhinweise und Vorsichtsmaßnahmen)

Larger doses may produce serious or even life-threatening manifestations of toxicity, particularly when given in association with sympathomimetic amines such as those used for their anorectic effects. (Fachinformation zu Levothyroxin und Liothyronin, Boxed Warning (umrahmter Warnhinweis))

WARNING: RISK OF THYROID C-CELL TUMORS In male and female rats, dulaglutide causes a dose-related and treatment-duration-dependent increase in the incidence of thyroid C-cell tumors (adenomas and carcinomas) after lifetime exposure. (Fachinformation zu Dulaglutid, Boxed Warning (umrahmter Warnhinweis))

Larger doses may produce serious or even life-threatening manifestations of toxicity, particularly when given in association with sympathomimetic amines such as those used for their anorectic effects. (Fachinformation zu Levothyroxin und Liothyronin, Boxed Warning (umrahmter Warnhinweis))

Larger doses may produce serious or even life-threatening manifestations of toxicity, particularly when given in association with sympathomimetic amines such as those used for their anorectic effects. (Fachinformation zu Levothyroxin und Liothyronin, Boxed Warning (umrahmter Warnhinweis))

Larger doses may produce serious or even life-threatening manifestations of toxicity, particularly when given in association with sympathomimetic amines such as those used for their anorectic effects. (Fachinformation zu Levothyroxin und Liothyronin, Boxed Warning (umrahmter Warnhinweis))

Reactions including anaphylaxis have been reported [see Adverse Reactions (6.2) ] High levels of FSH indicating primary gonadal failure Presence of uncontrolled non-gonadal endocrinopathies (e.g., thyroid, adrenal, or pituitary disorders) [see Indications and Usage (1.1 , 1.2 , 1.3) ] Hypersensitivity reactions to streptomycin or neomycin. (Fachinformation zu Follitropin, Gegenanzeigen)

Larger doses may produce serious or even life-threatening manifestations of toxicity, particularly when given in association with sympathomimetic amines such as those used for their anorectic effects. (Fachinformation zu Levothyroxin und Liothyronin, Boxed Warning (umrahmter Warnhinweis))

Larger doses may produce serious or even life-threatening manifestations of toxicity, particularly when given in association with sympathomimetic amines such as those used for their anorectic effects. (Fachinformation zu Levothyroxin und Liothyronin, Boxed Warning (umrahmter Warnhinweis))

Larger doses may produce serious or even life-threatening manifestations of toxicity, particularly when given in association with sympathomimetic amines such as those used for their anorectic effects. (Fachinformation zu Levothyroxin und Liothyronin, Boxed Warning (umrahmter Warnhinweis))

Do not take thyroid hormone replacement therapy within 2 hours of dosing with LANTHANUM CARBONATE. (Fachinformation zu Lanthancarbonat, Arzneimittelwechselwirkungen)

Larger doses may produce serious or even life-threatening manifestations of toxicity, particularly when given in association with sympathomimetic amines such as those used for their anorectic effects. (Fachinformation zu Levothyroxin und Liothyronin, Boxed Warning (umrahmter Warnhinweis))

Larger doses may produce serious or even life-threatening manifestations of toxicity, particularly when given in association with sympathomimetic amines such as those used for their anorectic effects. (Fachinformation zu Levothyroxin und Liothyronin, Boxed Warning (umrahmter Warnhinweis))

WARNING: RISK OF THYROID C-CELL TUMORS • Liraglutide causes dose-dependent and treatment-duration-dependent thyroid C-cell tumors at clinically relevant exposures in both genders of rats and mice. (Fachinformation zu Liraglutid, Boxed Warning (umrahmter Warnhinweis))

Larger doses may produce serious or even life-threatening manifestations of toxicity, particularly when given in association with sympathomimetic amines such as those used for their anorectic effects. (Fachinformation zu Levothyroxin und Liothyronin, Boxed Warning (umrahmter Warnhinweis))

Larger doses may produce serious or even life-threatening manifestations of toxicity, particularly when given in association with sympathomimetic amines such as those used for their anorectic effects. (Fachinformation zu Levothyroxin und Liothyronin, Boxed Warning (umrahmter Warnhinweis))

Larger doses may produce serious or even life-threatening manifestations of toxicity, particularly when given in association with sympathomimetic amines such as those used for their anorectic effects. (Fachinformation zu Levothyroxin und Liothyronin, Boxed Warning (umrahmter Warnhinweis))

Larger doses may produce serious or even life-threatening manifestations of toxicity, particularly when given in association with sympathomimetic amines such as those used for their anorectic effects. (Fachinformation zu Levothyroxin und Liothyronin, Boxed Warning (umrahmter Warnhinweis))

Larger doses may produce serious or even life-threatening manifestations of toxicity, particularly when given in association with sympathomimetic amines such as those used for their anorectic effects. (Fachinformation zu Levothyroxin und Liothyronin, Boxed Warning (umrahmter Warnhinweis))

Larger doses may produce serious or even life-threatening manifestations of toxicity, particularly when given in association with sympathomimetic amines such as those used for their anorectic effects. (Fachinformation zu Levothyroxin und Liothyronin, Boxed Warning (umrahmter Warnhinweis))

Patients suspected of developing thyrotoxicosis should be managed carefully to avoid abrupt withdrawal of beta-adrenergic blockade which might precipitate a thyroid storm. (Fachinformation zu Nadolol, Warnhinweise)

Larger doses may produce serious or even life-threatening manifestations of toxicity, particularly when given in association with sympathomimetic amines such as those used for their anorectic effects. (Fachinformation zu Levothyroxin und Liothyronin, Boxed Warning (umrahmter Warnhinweis))

Larger doses may produce serious or even life-threatening manifestations of toxicity, particularly when given in association with sympathomimetic amines such as those used for their anorectic effects. (Fachinformation zu Levothyroxin und Liothyronin, Boxed Warning (umrahmter Warnhinweis))

Larger doses may produce serious or even life-threatening manifestations of toxicity, particularly when given in association with sympathomimetic amines such as those used for their anorectic effects. (Fachinformation zu Levothyroxin und Liothyronin, Boxed Warning (umrahmter Warnhinweis))

Larger doses may produce serious or even life-threatening manifestations of toxicity, particularly when given in association with sympathomimetic amines such as those used for their anorectic effects. (Fachinformation zu Levothyroxin und Liothyronin, Boxed Warning (umrahmter Warnhinweis))

Larger doses may produce serious or even life-threatening manifestations of toxicity, particularly when given in association with sympathomimetic amines such as those used for their anorectic effects. (Fachinformation zu Levothyroxin und Liothyronin, Boxed Warning (umrahmter Warnhinweis))

Larger doses may produce serious or even life-threatening manifestations of toxicity, particularly when given in association with sympathomimetic amines such as those used for their anorectic effects. (Fachinformation zu Levothyroxin und Liothyronin, Boxed Warning (umrahmter Warnhinweis))

Patients suspected of developing thyrotoxicosis should be managed carefully to avoid abrupt withdrawal of beta-blockade which might precipitate a thyroid crisis. (Fachinformation zu Pindolol, Warnhinweise)

Larger doses may produce serious or even life-threatening manifestations of toxicity, particularly when given in association with sympathomimetic amines such as those used for their anorectic effects. (Fachinformation zu Levothyroxin und Liothyronin, Boxed Warning (umrahmter Warnhinweis))

Avoid abrupt withdrawal of beta-blockade, which may precipitate a thyroid storm. (Fachinformation zu Propranolol, Warnhinweise und Vorsichtsmaßnahmen)

Larger doses may produce serious or even life-threatening manifestations of toxicity, particularly when given in association with sympathomimetic amines such as those used for their anorectic effects. (Fachinformation zu Levothyroxin und Liothyronin, Boxed Warning (umrahmter Warnhinweis))

Larger doses may produce serious or even life-threatening manifestations of toxicity, particularly when given in association with sympathomimetic amines such as those used for their anorectic effects. (Fachinformation zu Levothyroxin und Liothyronin, Boxed Warning (umrahmter Warnhinweis))

Larger doses may produce serious or even life-threatening manifestations of toxicity, particularly when given in association with sympathomimetic amines such as those used for their anorectic effects. (Fachinformation zu Levothyroxin und Liothyronin, Boxed Warning (umrahmter Warnhinweis))

WARNING: RISK OF THYROID C-CELL TUMORS • In rodents, semaglutide causes dose-dependent and treatment-duration-dependent thyroid C-cell tumors at clinically relevant exposures. (Fachinformation zu Semaglutid, Boxed Warning (umrahmter Warnhinweis))

Larger doses may produce serious or even life-threatening manifestations of toxicity, particularly when given in association with sympathomimetic amines such as those used for their anorectic effects. (Fachinformation zu Levothyroxin und Liothyronin, Boxed Warning (umrahmter Warnhinweis))

Thyroid Abnormalities Avoid abrupt withdrawal of beta-blockade which might be followed by an exacerbation of symptoms of hyperthyroidism, including thyroid storm. (Fachinformation zu Sotalol, Warnhinweise und Vorsichtsmaßnahmen)

Larger doses may produce serious or even life-threatening manifestations of toxicity, particularly when given in association with sympathomimetic amines such as those used for their anorectic effects. (Fachinformation zu Levothyroxin und Liothyronin, Boxed Warning (umrahmter Warnhinweis))

Patients suspected of developing thyrotoxicosis should be managed carefully to avoid abrupt withdrawal of beta-adrenergic blocking agents that might precipitate a thyroid storm. (Fachinformation zu Timolol, Warnhinweise und Vorsichtsmaßnahmen)

WARNING: RISK OF THYROID C-CELL TUMORS In rats, tirzepatide causes dose-dependent and treatment-duration-dependent thyroid C-cell tumors at clinically relevant exposures. (Fachinformation zu Tirzepatid, Boxed Warning (umrahmter Warnhinweis))

People who have thyroid problems (hyperthyroidism) may have a higher chance of having a hypertensive crisis. (Fachinformation zu Tranylcypromin, Boxed Warning (umrahmter Warnhinweis))

Larger doses may produce serious or even life-threatening manifestations of toxicity, particularly when given in association with sympathomimetic amines such as those used for their anorectic effects. (Fachinformation zu Levothyroxin und Liothyronin, Boxed Warning (umrahmter Warnhinweis))

Larger doses may produce serious or even life-threatening manifestations of toxicity, particularly when given in association with sympathomimetic amines such as those used for their anorectic effects. (Fachinformation zu Levothyroxin und Liothyronin, Boxed Warning (umrahmter Warnhinweis))

Insulin or Oral Hypoglycemics — Initiating thyroid replacement therapy may cause increases in insulin or oral hypoglycemic requirements. (Fachinformation zu Levothyroxin und Liothyronin, Arzneimittelwechselwirkungen)

Abrupt withdrawal of β-blockade may precipitate a thyroid storm; therefore, patients suspected of developing thyrotoxicosis from whom acebutolol therapy is to be withdrawn should be monitored closely. (Fachinformation zu Acebutolol, Warnhinweise)

Levothyroxine The bioavailability of alendronate was slightly decreased when BINOSTO and levothyroxine were co-administered to healthy subjects [see Clinical Pharmacology (12.3) ] . (Fachinformation zu Alendronsäure, Arzneimittelwechselwirkungen)

Insulin or Oral Hypoglycemics — Initiating thyroid replacement therapy may cause increases in insulin or oral hypoglycemic requirements. (Fachinformation zu Levothyroxin und Liothyronin, Arzneimittelwechselwirkungen)

Insulin or Oral Hypoglycemics — Initiating thyroid replacement therapy may cause increases in insulin or oral hypoglycemic requirements. (Fachinformation zu Levothyroxin und Liothyronin, Arzneimittelwechselwirkungen)

Thyroid Abnormalities Nexterone inhibits peripheral conversion of throxine (T4) to triiodothyronine (T3) and may cause increased T3 levels, and increased levels of inactive reverse T3 (rT3) in clinically euthyroid patients. (Fachinformation zu Amiodaron, Warnhinweise und Vorsichtsmaßnahmen)

Drug Interactions Oral Anticoagulants — Thyroid hormones appear to increase catabolism of vitamin K-dependent clotting factors. (Fachinformation zu Levothyroxin und Liothyronin, Arzneimittelwechselwirkungen)

Drug Interactions Oral Anticoagulants — Thyroid hormones appear to increase catabolism of vitamin K-dependent clotting factors. (Fachinformation zu Levothyroxin und Liothyronin, Arzneimittelwechselwirkungen)

Abrupt withdrawal of beta blockade might precipitate a thyroid storm; therefore, patients suspected of developing thyrotoxicosis from whom TENORMIN therapy is to be withdrawn should be monitored closely. (Fachinformation zu Atenolol, Warnhinweise)

Abrupt withdrawal of beta blockade might precipitate a thyroid storm; therefore, patients suspected of developing thyrotoxicosis from whom atenolol and chlorthalidone therapy is to be withdrawn should be monitored closely. (Fachinformation zu Atenolol und Chlortalidon, Warnhinweise)

Monitor thyroid function before initiation of, and periodically throughout, treatment with INLYTA. (Fachinformation zu Axitinib, Warnhinweise und Vorsichtsmaßnahmen)

The therapy of myxedema coma requires simultaneous administration of glucocorticoids (See DOSAGE AND ADMINISTRATION). (Fachinformation zu Levothyroxin und Liothyronin, Vorsichtsmaßnahmen)

The therapy of myxedema coma requires simultaneous administration of glucocorticoids (See DOSAGE AND ADMINISTRATION). (Fachinformation zu Levothyroxin und Liothyronin, Vorsichtsmaßnahmen)

The therapy of myxedema coma requires simultaneous administration of glucocorticoids (See DOSAGE AND ADMINISTRATION). (Fachinformation zu Levothyroxin und Liothyronin, Vorsichtsmaßnahmen)

Abrupt withdrawal of beta-blockade might precipitate a thyroid storm; therefore, patients known or suspected of being thyrotoxic from whom betaxolol is to be withdrawn should be monitored closely (see Dosage and Administration: Cessation of therapy ). (Fachinformation zu Betaxolol, Warnhinweise)

Insulin or Oral Hypoglycemics — Initiating thyroid replacement therapy may cause increases in insulin or oral hypoglycemic requirements. (Fachinformation zu Levothyroxin und Liothyronin, Arzneimittelwechselwirkungen)

Monitor and replace thyroid hormone if needed. (Fachinformation zu Bexaroten, Warnhinweise und Vorsichtsmaßnahmen)

Laboratory Test Interactions Based on reports involving thiazides, bisoprolol fumarate and hydrochlorothiazide tablets may decrease serum levels of protein-bound iodine without signs of thyroid disturbance. (Fachinformation zu Bisoprolol und Hydrochlorothiazid, Vorsichtsmaßnahmen)

Drug Interactions Oral Anticoagulants — Thyroid hormones appear to increase catabolism of vitamin K-dependent clotting factors. (Fachinformation zu Levothyroxin und Liothyronin, Arzneimittelwechselwirkungen)

The therapy of myxedema coma requires simultaneous administration of glucocorticoids (See DOSAGE AND ADMINISTRATION). (Fachinformation zu Levothyroxin und Liothyronin, Vorsichtsmaßnahmen)

Insulin or Oral Hypoglycemics — Initiating thyroid replacement therapy may cause increases in insulin or oral hypoglycemic requirements. (Fachinformation zu Levothyroxin und Liothyronin, Arzneimittelwechselwirkungen)

The therapy of myxedema coma requires simultaneous administration of glucocorticoids (See DOSAGE AND ADMINISTRATION). (Fachinformation zu Levothyroxin und Liothyronin, Vorsichtsmaßnahmen)

The therapy of myxedema coma requires simultaneous administration of glucocorticoids (See DOSAGE AND ADMINISTRATION). (Fachinformation zu Levothyroxin und Liothyronin, Vorsichtsmaßnahmen)

Concomitant use with colesevelam hydrochloride may decrease the exposure of the following drugs: Drugs with a narrow therapeutic index (e.g., cyclosporine), phenytoin, thyroid hormone replacement therapy, warfarin, oral contraceptives containing ethinyl estradiol and norethindrone, olmesartan medoxomil, and sulfonylureas (glimepiride, glipizide, glyburide). (Fachinformation zu Colesevelam, Arzneimittelwechselwirkungen)

Drug Interactions Cholestyramine for Oral Suspension USP may delay or reduce the absorption of concomitant oral medication such as phenylbutazone, warfarin, thiazide diuretics (acidic), or propranolol (basic), as well as tetracycline, penicillin G, phenobarbital, thyroid and thyroxine preparations, estrogens and progestins, and digitalis. (Fachinformation zu Colestyramin, Arzneimittelwechselwirkungen)

Drug Interactions Oral Anticoagulants — Thyroid hormones appear to increase catabolism of vitamin K-dependent clotting factors. (Fachinformation zu Levothyroxin und Liothyronin, Arzneimittelwechselwirkungen)

Other metabolic events include a reduction in thyroid binding globulin and T4 with increased uptake of T3, but without disturbance of thyroid stimulating hormone or of free thyroxin index. (Fachinformation zu Danazol, Vorsichtsmaßnahmen)

Insulin or Oral Hypoglycemics — Initiating thyroid replacement therapy may cause increases in insulin or oral hypoglycemic requirements. (Fachinformation zu Levothyroxin und Liothyronin, Arzneimittelwechselwirkungen)

Insulin or Oral Hypoglycemics — Initiating thyroid replacement therapy may cause increases in insulin or oral hypoglycemic requirements. (Fachinformation zu Levothyroxin und Liothyronin, Arzneimittelwechselwirkungen)

The therapy of myxedema coma requires simultaneous administration of glucocorticoids (See DOSAGE AND ADMINISTRATION). (Fachinformation zu Levothyroxin und Liothyronin, Vorsichtsmaßnahmen)

In patients with thyroid disease or those taking thyroid medication, because of the possibility of cardiovascular toxicity, including arrhythmias. e. (Fachinformation zu Desipramin, Warnhinweise)

Estrogen, Oral Contraceptives — Estrogens tend to increase serum thyroxine-binding globulin (TBg). (Fachinformation zu Levothyroxin und Liothyronin, Arzneimittelwechselwirkungen)

The therapy of myxedema coma requires simultaneous administration of glucocorticoids (See DOSAGE AND ADMINISTRATION). (Fachinformation zu Levothyroxin und Liothyronin, Vorsichtsmaßnahmen)

Use in Thyroid Disorders and Hypermetabolic States Hypothyroidism may reduce the requirements for digoxin. (Fachinformation zu Digoxin, Warnhinweise und Vorsichtsmaßnahmen)

Estrogen, Oral Contraceptives — Estrogens tend to increase serum thyroxine-binding globulin (TBg). (Fachinformation zu Levothyroxin und Liothyronin, Arzneimittelwechselwirkungen)

Drug Interactions Oral Anticoagulants — Thyroid hormones appear to increase catabolism of vitamin K-dependent clotting factors. (Fachinformation zu Levothyroxin und Liothyronin, Arzneimittelwechselwirkungen)

Insulin or Oral Hypoglycemics — Initiating thyroid replacement therapy may cause increases in insulin or oral hypoglycemic requirements. (Fachinformation zu Levothyroxin und Liothyronin, Arzneimittelwechselwirkungen)

Insulin or Oral Hypoglycemics — Initiating thyroid replacement therapy may cause increases in insulin or oral hypoglycemic requirements. (Fachinformation zu Levothyroxin und Liothyronin, Arzneimittelwechselwirkungen)

Drug Interactions Oral Anticoagulants — Thyroid hormones appear to increase catabolism of vitamin K-dependent clotting factors. (Fachinformation zu Levothyroxin und Liothyronin, Arzneimittelwechselwirkungen)

Abnormal Thyroid Function Tests Dose-dependent decreases in serum T3 and T4 (free and total) values have been observed in patients taking APTIOM. (Fachinformation zu Eslicarbazepin, Warnhinweise und Vorsichtsmaßnahmen)

Abrupt withdrawal of beta blockade might precipitate a thyroid storm; therefore, monitor patients for signs of thyrotoxicosis when withdrawing beta blocking therapy. (Fachinformation zu Esmolol, Warnhinweise und Vorsichtsmaßnahmen)

Estrogen, Oral Contraceptives — Estrogens tend to increase serum thyroxine-binding globulin (TBg). (Fachinformation zu Levothyroxin und Liothyronin, Arzneimittelwechselwirkungen)

Estrogen, Oral Contraceptives — Estrogens tend to increase serum thyroxine-binding globulin (TBg). (Fachinformation zu Levothyroxin und Liothyronin, Arzneimittelwechselwirkungen)

Estrogen, Oral Contraceptives — Estrogens tend to increase serum thyroxine-binding globulin (TBg). (Fachinformation zu Levothyroxin und Liothyronin, Arzneimittelwechselwirkungen)

Estrogen, Oral Contraceptives — Estrogens tend to increase serum thyroxine-binding globulin (TBg). (Fachinformation zu Levothyroxin und Liothyronin, Arzneimittelwechselwirkungen)

Estrogen, Oral Contraceptives — Estrogens tend to increase serum thyroxine-binding globulin (TBg). (Fachinformation zu Levothyroxin und Liothyronin, Arzneimittelwechselwirkungen)

Insulin or Oral Hypoglycemics — Initiating thyroid replacement therapy may cause increases in insulin or oral hypoglycemic requirements. (Fachinformation zu Levothyroxin und Liothyronin, Arzneimittelwechselwirkungen)

The therapy of myxedema coma requires simultaneous administration of glucocorticoids (See DOSAGE AND ADMINISTRATION). (Fachinformation zu Levothyroxin und Liothyronin, Vorsichtsmaßnahmen)

The therapy of myxedema coma requires simultaneous administration of glucocorticoids (See DOSAGE AND ADMINISTRATION). (Fachinformation zu Levothyroxin und Liothyronin, Vorsichtsmaßnahmen)

The therapy of myxedema coma requires simultaneous administration of glucocorticoids (See DOSAGE AND ADMINISTRATION). (Fachinformation zu Levothyroxin und Liothyronin, Vorsichtsmaßnahmen)

The therapy of myxedema coma requires simultaneous administration of glucocorticoids (See DOSAGE AND ADMINISTRATION). (Fachinformation zu Levothyroxin und Liothyronin, Vorsichtsmaßnahmen)

Drug Interactions Oral Anticoagulants — Thyroid hormones appear to increase catabolism of vitamin K-dependent clotting factors. (Fachinformation zu Levothyroxin und Liothyronin, Arzneimittelwechselwirkungen)

Estrogen, Oral Contraceptives — Estrogens tend to increase serum thyroxine-binding globulin (TBg). (Fachinformation zu Levothyroxin und Liothyronin, Arzneimittelwechselwirkungen)

Thyroid hormones High-doses (> 80 mg) of furosemide may inhibit the binding of thyroid hormones to carrier proteins and result in transient increase in free thyroid hormones, followed by an overall decrease in total thyroid hormone levels. (Fachinformation zu Furosemid, Arzneimittelwechselwirkungen)

Insulin or Oral Hypoglycemics — Initiating thyroid replacement therapy may cause increases in insulin or oral hypoglycemic requirements. (Fachinformation zu Levothyroxin und Liothyronin, Arzneimittelwechselwirkungen)

Insulin or Oral Hypoglycemics — Initiating thyroid replacement therapy may cause increases in insulin or oral hypoglycemic requirements. (Fachinformation zu Levothyroxin und Liothyronin, Arzneimittelwechselwirkungen)

Insulin or Oral Hypoglycemics — Initiating thyroid replacement therapy may cause increases in insulin or oral hypoglycemic requirements. (Fachinformation zu Levothyroxin und Liothyronin, Arzneimittelwechselwirkungen)

Insulin or Oral Hypoglycemics — Initiating thyroid replacement therapy may cause increases in insulin or oral hypoglycemic requirements. (Fachinformation zu Levothyroxin und Liothyronin, Arzneimittelwechselwirkungen)

Insulin or Oral Hypoglycemics — Initiating thyroid replacement therapy may cause increases in insulin or oral hypoglycemic requirements. (Fachinformation zu Levothyroxin und Liothyronin, Arzneimittelwechselwirkungen)

The therapy of myxedema coma requires simultaneous administration of glucocorticoids (See DOSAGE AND ADMINISTRATION). (Fachinformation zu Levothyroxin und Liothyronin, Vorsichtsmaßnahmen)

Drug Interactions Oral Anticoagulants — Thyroid hormones appear to increase catabolism of vitamin K-dependent clotting factors. (Fachinformation zu Levothyroxin und Liothyronin, Arzneimittelwechselwirkungen)

Insulin or Oral Hypoglycemics — Initiating thyroid replacement therapy may cause increases in insulin or oral hypoglycemic requirements. (Fachinformation zu Levothyroxin und Liothyronin, Arzneimittelwechselwirkungen)

…recommended that appropriate references first be consulted to determine the usual precautions for the use of the other drug; e.g., when epinephrine is injected along with hyaluronidase, the precautions for the use of epinephrine in cardiovascular disease, thyroid disease, diabetes, digital nerve block, ischemia of the fingers and toes etc., should be observed. (Fachinformation zu Hyaluronidase, Arzneimittelwechselwirkungen)

The therapy of myxedema coma requires simultaneous administration of glucocorticoids (See DOSAGE AND ADMINISTRATION). (Fachinformation zu Levothyroxin und Liothyronin, Vorsichtsmaßnahmen)

…levels of the drug; Patients with history of urinary retention, or history of narrow-angle glaucoma because of the drug's anticholinergic properties; hyperthyroid patients or those on thyroid medication because of the possibility of cardiovascular toxicity; patients with a history of seizure disorder because this drug has been shown to lower the seizure threshold;… (Fachinformation zu Imipramin, Warnhinweise)

Insulin or Oral Hypoglycemics — Initiating thyroid replacement therapy may cause increases in insulin or oral hypoglycemic requirements. (Fachinformation zu Levothyroxin und Liothyronin, Arzneimittelwechselwirkungen)

Insulin or Oral Hypoglycemics — Initiating thyroid replacement therapy may cause increases in insulin or oral hypoglycemic requirements. (Fachinformation zu Levothyroxin und Liothyronin, Arzneimittelwechselwirkungen)

Insulin or Oral Hypoglycemics — Initiating thyroid replacement therapy may cause increases in insulin or oral hypoglycemic requirements. (Fachinformation zu Levothyroxin und Liothyronin, Arzneimittelwechselwirkungen)

Insulin or Oral Hypoglycemics — Initiating thyroid replacement therapy may cause increases in insulin or oral hypoglycemic requirements. (Fachinformation zu Levothyroxin und Liothyronin, Arzneimittelwechselwirkungen)

Insulin or Oral Hypoglycemics — Initiating thyroid replacement therapy may cause increases in insulin or oral hypoglycemic requirements. (Fachinformation zu Levothyroxin und Liothyronin, Arzneimittelwechselwirkungen)

Thyroid function should be monitored periodically. (Fachinformation zu Interferon beta-1a, Warnhinweise und Vorsichtsmaßnahmen)

Estrogen, Oral Contraceptives — Estrogens tend to increase serum thyroxine-binding globulin (TBg). (Fachinformation zu Levothyroxin und Liothyronin, Arzneimittelwechselwirkungen)

Estrogen, Oral Contraceptives — Estrogens tend to increase serum thyroxine-binding globulin (TBg). (Fachinformation zu Levothyroxin und Liothyronin, Arzneimittelwechselwirkungen)

Thyroid Function Abnormalities : Decreases in thyroid function may occur; perform tests where clinically indicated. (Fachinformation zu Lanreotid, Warnhinweise und Vorsichtsmaßnahmen)

Estrogen, Oral Contraceptives — Estrogens tend to increase serum thyroxine-binding globulin (TBg). (Fachinformation zu Levothyroxin und Liothyronin, Arzneimittelwechselwirkungen)

Estrogen, Oral Contraceptives — Estrogens tend to increase serum thyroxine-binding globulin (TBg). (Fachinformation zu Levothyroxin und Liothyronin, Arzneimittelwechselwirkungen)

Insulin or Oral Hypoglycemics — Initiating thyroid replacement therapy may cause increases in insulin or oral hypoglycemic requirements. (Fachinformation zu Levothyroxin und Liothyronin, Arzneimittelwechselwirkungen)

Insulin or Oral Hypoglycemics — Initiating thyroid replacement therapy may cause increases in insulin or oral hypoglycemic requirements. (Fachinformation zu Levothyroxin und Liothyronin, Arzneimittelwechselwirkungen)

• Hypothyroidism and Hyperthyroidism: Monitor thyroid function regularly ( 5.7 ). (Fachinformation zu Lithium, Warnhinweise und Vorsichtsmaßnahmen)

Estrogen, Oral Contraceptives — Estrogens tend to increase serum thyroxine-binding globulin (TBg). (Fachinformation zu Levothyroxin und Liothyronin, Arzneimittelwechselwirkungen)

Estrogen, Oral Contraceptives — Estrogens tend to increase serum thyroxine-binding globulin (TBg). (Fachinformation zu Levothyroxin und Liothyronin, Arzneimittelwechselwirkungen)

Insulin or Oral Hypoglycemics — Initiating thyroid replacement therapy may cause increases in insulin or oral hypoglycemic requirements. (Fachinformation zu Levothyroxin und Liothyronin, Arzneimittelwechselwirkungen)

The therapy of myxedema coma requires simultaneous administration of glucocorticoids (See DOSAGE AND ADMINISTRATION). (Fachinformation zu Levothyroxin und Liothyronin, Vorsichtsmaßnahmen)

Estrogen, Oral Contraceptives — Estrogens tend to increase serum thyroxine-binding globulin (TBg). (Fachinformation zu Levothyroxin und Liothyronin, Arzneimittelwechselwirkungen)

Insulin or Oral Hypoglycemics — Initiating thyroid replacement therapy may cause increases in insulin or oral hypoglycemic requirements. (Fachinformation zu Levothyroxin und Liothyronin, Arzneimittelwechselwirkungen)

The therapy of myxedema coma requires simultaneous administration of glucocorticoids (See DOSAGE AND ADMINISTRATION). (Fachinformation zu Levothyroxin und Liothyronin, Vorsichtsmaßnahmen)

Insulin or Oral Hypoglycemics — Initiating thyroid replacement therapy may cause increases in insulin or oral hypoglycemic requirements. (Fachinformation zu Levothyroxin und Liothyronin, Arzneimittelwechselwirkungen)

Estrogen, Oral Contraceptives — Estrogens tend to increase serum thyroxine-binding globulin (TBg). (Fachinformation zu Levothyroxin und Liothyronin, Arzneimittelwechselwirkungen)

Estrogen, Oral Contraceptives — Estrogens tend to increase serum thyroxine-binding globulin (TBg). (Fachinformation zu Levothyroxin und Liothyronin, Arzneimittelwechselwirkungen)

Estrogen, Oral Contraceptives — Estrogens tend to increase serum thyroxine-binding globulin (TBg). (Fachinformation zu Levothyroxin und Liothyronin, Arzneimittelwechselwirkungen)

Estrogen, Oral Contraceptives — Estrogens tend to increase serum thyroxine-binding globulin (TBg). (Fachinformation zu Levothyroxin und Liothyronin, Arzneimittelwechselwirkungen)

Estrogen, Oral Contraceptives — Estrogens tend to increase serum thyroxine-binding globulin (TBg). (Fachinformation zu Levothyroxin und Liothyronin, Arzneimittelwechselwirkungen)

Thyroid Function Abnormalities MYCAPSSA suppresses the secretion of thyroid-stimulating hormone, which may result in hypothyroidism. (Fachinformation zu Octreotid, Warnhinweise und Vorsichtsmaßnahmen)

The therapy of myxedema coma requires simultaneous administration of glucocorticoids (See DOSAGE AND ADMINISTRATION). (Fachinformation zu Levothyroxin und Liothyronin, Vorsichtsmaßnahmen)

Drug Interactions and Decreased Vitamin Absorption ORLISTAT may interact with concomitant drugs including cyclosporine, levothyroxine, warfarin, amiodarone, antiepileptic drugs, and antiretroviral drugs [see Drug Interactions (7) ]. (Fachinformation zu Orlistat, Warnhinweise und Vorsichtsmaßnahmen)

Monitoring pituitary function (e.g., thyroid, adrenal, gonadal) prior to initiation of therapy with SIGNIFOR LAR, as well as periodically during treatment, as clinically appropriate, is recommended. (Fachinformation zu Pasireotid, Warnhinweise und Vorsichtsmaßnahmen)

Hypothyroidism : Monitor thyroid tests at baseline, during treatment and as clinically indicated and manage hypothyroidism as appropriate. (Fachinformation zu Pazopanib, Warnhinweise und Vorsichtsmaßnahmen)

Drug Interactions Oral Anticoagulants — Thyroid hormones appear to increase catabolism of vitamin K-dependent clotting factors. (Fachinformation zu Levothyroxin und Liothyronin, Arzneimittelwechselwirkungen)

Insulin or Oral Hypoglycemics — Initiating thyroid replacement therapy may cause increases in insulin or oral hypoglycemic requirements. (Fachinformation zu Levothyroxin und Liothyronin, Arzneimittelwechselwirkungen)

Insulin or Oral Hypoglycemics — Initiating thyroid replacement therapy may cause increases in insulin or oral hypoglycemic requirements. (Fachinformation zu Levothyroxin und Liothyronin, Arzneimittelwechselwirkungen)

Insulin or Oral Hypoglycemics — Initiating thyroid replacement therapy may cause increases in insulin or oral hypoglycemic requirements. (Fachinformation zu Levothyroxin und Liothyronin, Arzneimittelwechselwirkungen)

The therapy of myxedema coma requires simultaneous administration of glucocorticoids (See DOSAGE AND ADMINISTRATION). (Fachinformation zu Levothyroxin und Liothyronin, Vorsichtsmaßnahmen)

The therapy of myxedema coma requires simultaneous administration of glucocorticoids (See DOSAGE AND ADMINISTRATION). (Fachinformation zu Levothyroxin und Liothyronin, Vorsichtsmaßnahmen)

Estrogen, Oral Contraceptives — Estrogens tend to increase serum thyroxine-binding globulin (TBg). (Fachinformation zu Levothyroxin und Liothyronin, Arzneimittelwechselwirkungen)

Hypothyroidism Adults: Clinical trials with quetiapine demonstrated dose-related decreases in thyroid hormone levels. (Fachinformation zu Quetiapin, Warnhinweise und Vorsichtsmaßnahmen)

Insulin or Oral Hypoglycemics — Initiating thyroid replacement therapy may cause increases in insulin or oral hypoglycemic requirements. (Fachinformation zu Levothyroxin und Liothyronin, Arzneimittelwechselwirkungen)

Substitute non-enzyme inducing therapies at least 2 weeks prior to initiation of irinotecan therapy Decrease irinotecan and active metabolite exposure Levothyroxine Decrease exposure Losartan Parent Decrease AUC by 30% Active metabolite (E3174) Decrease AUC by 40% Methadone In patients well-stabilized on methadone, concomitant administration of rifampin resulted… (Fachinformation zu Rifampicin, Arzneimittelwechselwirkungen)

…levonorgestrel Immunosuppressants Cyclosporine, tacrolimus Methylxanthines Theophylline Narcotic analgesics Methadone Phosphodiesterase-5 (PDE-5) Inhibitors Sildenafil Thyroid preparations Levothyroxine Tricyclic antidepressants Amitriptyline, nortriptyline 7.5 Other Interactions The conversion of PRIFTIN to 25-desacetyl rifapentine is mediated by an esterase enzyme. (Fachinformation zu Rifapentin, Arzneimittelwechselwirkungen)

Drug Interactions Oral Anticoagulants — Thyroid hormones appear to increase catabolism of vitamin K-dependent clotting factors. (Fachinformation zu Levothyroxin und Liothyronin, Arzneimittelwechselwirkungen)

Insulin or Oral Hypoglycemics — Initiating thyroid replacement therapy may cause increases in insulin or oral hypoglycemic requirements. (Fachinformation zu Levothyroxin und Liothyronin, Arzneimittelwechselwirkungen)

Insulin or Oral Hypoglycemics — Initiating thyroid replacement therapy may cause increases in insulin or oral hypoglycemic requirements. (Fachinformation zu Levothyroxin und Liothyronin, Arzneimittelwechselwirkungen)

For oral medication where a reduction in the bioavailability of that medication would have a clinically significant effect on its safety or efficacy (e.g., cyclosporine, tacrolimus, levothyroxine), consider separation of the timing of the administration of the two drugs [see Clinical Pharmacology (12.3) ] . (Fachinformation zu Sevelamer, Arzneimittelwechselwirkungen)

Insulin or Oral Hypoglycemics — Initiating thyroid replacement therapy may cause increases in insulin or oral hypoglycemic requirements. (Fachinformation zu Levothyroxin und Liothyronin, Arzneimittelwechselwirkungen)

Insulin or Oral Hypoglycemics — Initiating thyroid replacement therapy may cause increases in insulin or oral hypoglycemic requirements. (Fachinformation zu Levothyroxin und Liothyronin, Arzneimittelwechselwirkungen)

Hypothyroidism: Monitor thyroid function periodically as hypothyroidism may occur or worsen after initiation of somatropin. (Fachinformation zu Somatropin, Warnhinweise und Vorsichtsmaßnahmen)

• Impairment of Thyroid Stimulating Hormone Suppression (TSH) in DTC : Monitor TSH monthly and adjust thyroid replacement therapy in patients with thyroid cancer. (Fachinformation zu Sorafenib, Warnhinweise und Vorsichtsmaßnahmen)

• Thyroid Dysfunction : Monitor thyroid function at baseline, periodically during treatment, and as clinically indicated. (Fachinformation zu Sunitinib, Warnhinweise und Vorsichtsmaßnahmen)

Drug-Laboratory Test Interactions There are postmarketing reports of T 4 elevations in postmenopausal patients taking tamoxifen that may be explained by increases in thyroid-binding globulin. (Fachinformation zu Tamoxifen, Arzneimittelwechselwirkungen)

The therapy of myxedema coma requires simultaneous administration of glucocorticoids (See DOSAGE AND ADMINISTRATION). (Fachinformation zu Levothyroxin und Liothyronin, Vorsichtsmaßnahmen)

Caution is advised in patients with history of urinary retention because of the drug's anticholinergic properties; hyperthyroid patients or those on thyroid medication because of the possibility of cardiovascular toxicity; patients with a history of seizure disorder, because this drug has been shown to lower the seizure threshold; patients receiving guanethidine… (Fachinformation zu Trimipramin, Warnhinweise)

Estrogen, Oral Contraceptives — Estrogens tend to increase serum thyroxine-binding globulin (TBg). (Fachinformation zu Levothyroxin und Liothyronin, Arzneimittelwechselwirkungen)

Drug Interactions Oral Anticoagulants — Thyroid hormones appear to increase catabolism of vitamin K-dependent clotting factors. (Fachinformation zu Levothyroxin und Liothyronin, Arzneimittelwechselwirkungen)

Drug Interactions Oral Anticoagulants — Thyroid hormones appear to increase catabolism of vitamin K-dependent clotting factors. (Fachinformation zu Levothyroxin und Liothyronin, Arzneimittelwechselwirkungen)

Guanethidine or similarly acting compounds; thyroid medication; alcohol, barbiturates and other CNS depressants; and disulfiram – see WARNINGS section. (Fachinformation zu Amitriptylin, Arzneimittelwechselwirkungen)

Abrupt withdrawal of beta-blockade may be followed by an exacerbation of the symptoms of hyperthyroidism or may precipitate thyroid storm. (Fachinformation zu Bisoprolol, Warnhinweise)

Cytologic abnormalities characterized by giant, hyperchromatic nuclei have been reported in lymph nodes, pancreas, thyroid, adrenal glands, liver, and bone marrow. (Fachinformation zu Busulfan, Warnhinweise)

…dicumarol, dihydropyridine calcium channel blockers (e.g., felodipine), doxycycline, ethosuximide, everolimus, felbamate, glucocorticoids, haloperidol, imatinib, itraconazole, lamotrigine, levothyroxine, lorazepam, methadone, methsuxamide, mianserin, midazolam, mirtazapine, nefazodone, olanzapine, oral and other hormonal contraceptives, oxcarbazepine, paliperidone, phenytoin,… (Fachinformation zu Carbamazepin, Arzneimittelwechselwirkungen)

Abrupt withdrawal of β-blockade may be followed by an exacerbation of the symptoms of hyperthyroidism or may precipitate thyroid storm. (Fachinformation zu Carvedilol, Warnhinweise und Vorsichtsmaßnahmen)

Cholestyramine or Colestipol - Cholestyramine or colestipol binds both T 4 and T 3 in the intestine, thus impairing absorption of these thyroid hormones. (Fachinformation zu Levothyroxin und Liothyronin, Arzneimittelwechselwirkungen)

Secondary malignancies (urinary tract cancer, myelodysplasia, acute leukemias, lymphomas, thyroid cancer, and sarcomas) have been reported in patients treated with cyclophosphamide-containing regimens . (Fachinformation zu Cyclophosphamid, Warnhinweise und Vorsichtsmaßnahmen)

Cases of myelodysplastic syndrome, acute leukemias, lymphomas, thyroid cancers, and sarcomas have occurred and may develop several years after chemotherapy has been discontinued. (Fachinformation zu Ifosfamid, Warnhinweise und Vorsichtsmaßnahmen)

Hypothyroidism has been reported in thyroidectomy patients undergoing levothyroxine replacement. (Fachinformation zu Imatinib, Warnhinweise und Vorsichtsmaßnahmen)

Warnings Potassium iodide can cause fetal harm, abnormal thyroid function, and goiter when administered to a pregnant woman. (Fachinformation zu Kaliumiodid, Warnhinweise)

Thyroid Disorders Both hypothyroidism and hyperthyroidism have been reported [see Adverse Reactions (6.2) ] . (Fachinformation zu Lenalidomid, Warnhinweise und Vorsichtsmaßnahmen)

Other Medications Used for the Management of Fanconi Syndrome PROCYSBI can be administered with other electrolyte and mineral replacements necessary for management of Fanconi syndrome, as well as vitamin D and thyroid hormone. (Fachinformation zu Mercaptamin (Cysteamin), Arzneimittelwechselwirkungen)

Free thyroid hormone levels remain unchanged, however, and there is no clinical evidence of thyroid dysfunction. (Fachinformation zu Methyltestosteron, Vorsichtsmaßnahmen)

Thyrotoxicosis: Abrupt withdrawal in patients with thyrotoxicosis might precipitate a thyroid storm. (Fachinformation zu Metoprolol, Warnhinweise und Vorsichtsmaßnahmen)

Abrupt withdrawal in thyrotoxicosis might precipitate a thyroid storm. (Fachinformation zu Metoprolol und Hydrochlorothiazid, Warnhinweise und Vorsichtsmaßnahmen)

EMROSI may induce hyperpigmentation in many organs, including nails, bone, skin, eyes, thyroid, visceral tissue, oral cavity (teeth, mucosa, alveolar bone), sclerae and heart valves. (Fachinformation zu Minocyclin, Warnhinweise und Vorsichtsmaßnahmen)

In cases of cognitive dysfunction, thyroid function should be evaluated as mitotane may induce hypothyroidism. (Fachinformation zu Mitotan, Warnhinweise und Vorsichtsmaßnahmen)

Losartan, glipizide and levothyroxine did not show any changes in exposure when co-administered with LOKELMA. (Fachinformation zu Natrium-Zirconium-Cyclosilicat, Arzneimittelwechselwirkungen)

Abrupt withdrawal of β-blockers may be followed by an exacerbation of the symptoms of hyperthyroidism or may precipitate a thyroid storm. (Fachinformation zu Nebivolol, Warnhinweise und Vorsichtsmaßnahmen)

Great care is required if Pamelor is given to hyperthyroid patients or to those receiving thyroid medication, since cardiac arrhythmias may develop. (Fachinformation zu Nortriptylin, Warnhinweise)

…performed, the following concomitant drugs were used in at least 10% of patients in either or both Sjogren's efficacy studies: acetylsalicylic acid, artificial tears, calcium, conjugated estrogens, hydroxychloroquine sulfate, ibuprofen, levothyroxine sodium, medroxyprogesterone acetate, methotrexate, multivitamins, naproxen, omeprazole, paracetamol, and prednisone. (Fachinformation zu Pilocarpin, Arzneimittelwechselwirkungen)

On rare occasions, hyperthyroid patients or those receiving thyroid medication may develop arrhythmias when this drug is given. (Fachinformation zu Protriptylin, Warnhinweise)

Free thyroid hormone concentrations remain unchanged, however, and there is no clinical evidence of thyroid dysfunction. (Fachinformation zu Testosteron, Warnhinweise und Vorsichtsmaßnahmen)

Effect on Ketone and Thyroid Function Tests Valproate is partially eliminated in the urine as a keto-metabolite which may lead to a false interpretation of the urine ketone test. (Fachinformation zu Valproat-Seminatrium (Divalproex), Warnhinweise und Vorsichtsmaßnahmen)

Effect on Ketone and Thyroid Function Tests Valproate is partially eliminated in the urine as a keto-metabolite which may lead to a false interpretation of the urine ketone test. (Fachinformation zu Valproinsäure, Warnhinweise und Vorsichtsmaßnahmen)

Hypocalcemia and Mineral Metabolism Preexisting hypocalcemia and disturbances of mineral metabolism (e.g., hypoparathyroidism, thyroid surgery, parathyroid surgery; malabsorption syndromes, excision of small intestine) must be effectively treated before initiating therapy with Reclast. (Fachinformation zu Zoledronsäure, Warnhinweise und Vorsichtsmaßnahmen)

Thyroid-stimulating hormone, total thyroxine, and thyrotropin-releasing hormone response are not affected. (Fachinformation zu Fenoprofen, Arzneimittelwechselwirkungen)

…adjustment is needed when SINGULAIR is co-administered with theophylline, prednisone, prednisolone, oral contraceptives, fexofenadine, digoxin, warfarin, gemfibrozil, itraconazole, thyroid hormones, sedative hypnotics, non-steroidal anti-inflammatory agents, benzodiazepines, decongestants, and Cytochrome P450 (CYP) enzyme inducers [see Clinical Pharmacology (12.3)… (Fachinformation zu Montelukast, Arzneimittelwechselwirkungen)